A number of other research firms have also weighed in on EBS. Cantor Fitzgerald increased their price objective on Emergent BioSolutions from $50.00 to $55.00 in a research note on Thursday, January 20th. Zacks Investment Research upgraded shares of Emergent BioSolutions from a strong sell rating to a hold rating and set a $45.00 price target for the company in a report on Friday, February 18th. Benchmark upgraded shares of Emergent BioSolutions from a hold rating to a buy rating and set a $77.00 price target for the company in a report on Thursday, January 20th. Cowen lowered their price target on shares of Emergent BioSolutions from $40.00 to $30.00 in a report on Friday. Finally, Chardan Capital lowered their price target on shares of Emergent BioSolutions from $75.00 to $65.00 in a report on Friday. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, Emergent BioSolutions has an average rating of Hold and an average price target of $48.86.
Emergent BioSolutions stock traded down $4.23 during mid-day trading on Friday, hitting $32.38. The company’s stock had a trading volume of 1,301,767 shares, compared to its average volume of 501,423. The business has a 50 day moving average price of $40.91 and a 200-day moving average price of $43.56. The company has a debt-to-equity ratio of 0.50, a current ratio of 3.40 and a quick ratio of 2.46. Emergent BioSolutions has a 12 month low of $29.88 and a 12 month high of $68.03. The stock has a market cap of $1.63 billion, a price-to-earnings ratio of 11.13 and a beta of 0.88.
Hedge funds and other institutional investors have recently modified their holdings of the business. Cutler Group LP raised its holdings in Emergent BioSolutions by 250.0% in the 1st quarter. Cutler Group LP now owns 700 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 500 shares in the last quarter. Covestor Ltd bought a new position in shares of Emergent BioSolutions in the 4th quarter worth about $49,000. Schroder Investment Management Group bought a new position in shares of Emergent BioSolutions in the 4th quarter worth about $54,000. First Bank & Trust increased its stake in shares of Emergent BioSolutions by 32.3% in the 4th quarter. First Bank & Trust now owns 1,850 shares of the biopharmaceutical company’s stock worth $81,000 after acquiring an additional 452 shares in the last quarter. Finally, Point72 Hong Kong Ltd bought a new position in shares of Emergent BioSolutions in the 3rd quarter worth about $106,000. Institutional investors and hedge funds own 85.51% of the company’s stock.
Emergent BioSolutions Company Profile (Get Rating)
Emergent BioSolutions Inc, a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care.
- Get a free copy of the StockNews.com research report on Emergent BioSolutions (EBS)
- Why is Chevron Stock Falling After Strong Earnings?
- MarketBeat: Week in Review 4/25 – 4/29
- Apple’s Numbers Complete Trifecta
- Rogers Communication Stock Should Be Launching Higher
- O’Reilly Automotive Hits A Pothole
Receive News & Ratings for Emergent BioSolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent BioSolutions and related companies with MarketBeat.com's FREE daily email newsletter.